Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Targeting the Notch Signalling Pathway for the Treatment of Breast Cancer

EF 2013-14

Résumé
In 2013, an estimated 23,800 women will be diagnosed with breast cancer in Canada and over 5,000 will die from it. Although breast cancer mortality rates are at the lowest they have been since the 1950’s due to advances made in breast cancer research and evidence-based medicine, chemo resistance and recurrent metastases continue to contribute significantly to cancer mortality rates. The adaptability and heterogeneity of tumours endow them with drug-resistance and the capacity for metastasis. In the past decade a cellular hierarchy has been theoretically established in numerous hematopoietic and solid tumours, with a minority population of pluripotent progenitor cells, termed “cancer stem cells” (CSCs) or “tumor-initiating cells”, which sit at the apex of this hierarchy. CSCs share certain characteristics with their normal stem cell counterparts including the capacity to self renew indefinitely and differentiate into any of the heterogeneous cell types found in a tumour. They are thought to be the culprit in disease recurrence, metastasis, and chemo resistance. In theory, combinatorial treatment of cancer with a CSC targeting agent and conventional chemotherapy should both regress the bulk of the tumour but also confer long-term disease-free survival to the patient. Thus, there has been a substantial effort to characterize CSCs in order to develop therapies that target this tumourigenic population. One approach is to target key developmental signaling pathways that control self-renewal and differentiation of normal mammary stem cells, but are dysregulated in the malignant cells possessing a CSC phenotype. Targeting the Notch signaling pathway has been a promising approach to developing a breast cancer therapy as Notch has been shown to be aberrantly activated in a number of breast tumour subtypes as well as breast CSCs. A class of chemical inhibitors known as gamma-secretase inhibitors (GSIs) have had the greatest preclinical and clinical success in achieving these ends. Mice treated with GSIs not only display tumour regression and sustained survival, but their tumours contain a significantly lowered frequency of breast CSC. Unfortunately, the effects of GSI’s are relatively non-specific and quite potent, and clinical trial patients often experience adverse side effects due to the toxicity of GSIs in the gut. This narrows the therapeutic window within which patients experience beneficial effects from oral treatment with GSIs. My project is aimed at identifying and validating a specific, small-molecule Notch inhibitor that will be an effective form of breast cancer therapy with respect to both potency and diminishing unwanted side effects. I predict such an agent will be able to target the breast CSC population within breast tumours to yield recurrence-free survival. I will achieve this by conducting a high throughput chemical screen to identify compounds that target the transcriptional function of the Notch pathway and that are specific to one or another human Notch receptor. I will then validate the hits for their Notch inhibitory potential in vitro and in vivo using transcriptomic and proteomic techniques. Hits will also be tested for their capacity to inhibit the growth of breast CSC using a 3D in vitro breast cancer model. Regular oral treatment of mice bearing human breast tumour xenografts with candidate inhibitors and secondary transplantation assays will demonstrate this same potential in vivo in comparison to conventional chemotherapies or to treatment regimens that combine an oral Notch inhibitor with chemotherapy. I ultimately hope to identify a selective, chemical Notch inhibitor that yields great therapeutic potential and can be translated into a clinical setting for the treatment of breast cancer.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
311845
Name
Muzlera Carlos U
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeting the Notch Signalling Pathway for the Treatment of Breast Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Cancer Stem Cells; Chemotherapy; Combinatorial Cancer Treatment; Gene Expression Profiling; Notch Signaling; Transplantation Assays
Abstract
In 2013, an estimated 23,800 women will be diagnosed with breast cancer in Canada and over 5,000 will die from it. Although breast cancer mortality rates are at the lowest they have been since the 1950’s due to advances made in breast cancer research and evidence-based medicine, chemo resistance and recurrent metastases continue to contribute significantly to cancer mortality rates. The adaptability and heterogeneity of tumours endow them with drug-resistance and the capacity for metastasis. In the past decade a cellular hierarchy has been theoretically established in numerous hematopoietic and solid tumours, with a minority population of pluripotent progenitor cells, termed “cancer stem cells” (CSCs) or “tumor-initiating cells”, which sit at the apex of this hierarchy. CSCs share certain characteristics with their normal stem cell counterparts including the capacity to self renew indefinitely and differentiate into any of the heterogeneous cell types found in a tumour. They are thought to be the culprit in disease recurrence, metastasis, and chemo resistance. In theory, combinatorial treatment of cancer with a CSC targeting agent and conventional chemotherapy should both regress the bulk of the tumour but also confer long-term disease-free survival to the patient. Thus, there has been a substantial effort to characterize CSCs in order to develop therapies that target this tumourigenic population. One approach is to target key developmental signaling pathways that control self-renewal and differentiation of normal mammary stem cells, but are dysregulated in the malignant cells possessing a CSC phenotype. Targeting the Notch signaling pathway has been a promising approach to developing a breast cancer therapy as Notch has been shown to be aberrantly activated in a number of breast tumour subtypes as well as breast CSCs. A class of chemical inhibitors known as gamma-secretase inhibitors (GSIs) have had the greatest preclinical and clinical success in achieving these ends. Mice treated with GSIs not only display tumour regression and sustained survival, but their tumours contain a significantly lowered frequency of breast CSC. Unfortunately, the effects of GSI’s are relatively non-specific and quite potent, and clinical trial patients often experience adverse side effects due to the toxicity of GSIs in the gut. This narrows the therapeutic window within which patients experience beneficial effects from oral treatment with GSIs. My project is aimed at identifying and validating a specific, small-molecule Notch inhibitor that will be an effective form of breast cancer therapy with respect to both potency and diminishing unwanted side effects. I predict such an agent will be able to target the breast CSC population within breast tumours to yield recurrence-free survival. I will achieve this by conducting a high throughput chemical screen to identify compounds that target the transcriptional function of the Notch pathway and that are specific to one or another human Notch receptor. I will then validate the hits for their Notch inhibitory potential in vitro and in vivo using transcriptomic and proteomic techniques. Hits will also be tested for their capacity to inhibit the growth of breast CSC using a 3D in vitro breast cancer model. Regular oral treatment of mice bearing human breast tumour xenografts with candidate inhibitors and secondary transplantation assays will demonstrate this same potential in vivo in comparison to conventional chemotherapies or to treatment regimens that combine an oral Notch inhibitor with chemotherapy. I ultimately hope to identify a selective, chemical Notch inhibitor that yields great therapeutic potential and can be translated into a clinical setting for the treatment of breast cancer.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Muzlera, Carlos U
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~